Biopharmaceutical medicines represent a growing share of the global pharmaceutical market, with $228 billion in global sales in 2016. As many of these products face the loss of patent protection, biosimilar versions of these molecules may now enter the market, causing a shift in market share and driving changes in pharmaceutical companies’ strategies.
Biopharmaceutical medicines represent a growing share of the global pharmaceutical market, with $228 billion in global sales in 2016. As many of these products face the loss of patent protection, biosimilar versions of these molecules may now enter the market, causing a shift in market share and driving changes in pharmaceutical companies’ strategies.
Writing in the June 8, 2017, issue of Frontiers in Pharmacology, Evelien Moorkens, a PhD candidate in the Department of Pharmaceutical and Pharmacological Sciences at Katholieke Universiteit Leuven, Leuven, Belgium, and coauthors present a snapshot of the investment and development strategies used by the top 25 players in the global pharmaceutical market. The authors use publicly available data from 2015 global prescription drug sales; manufacturing plans; development programs; acquisition and collaboration agreements; and portfolios and pipelines of biosimilar, originator, and next-generation biopharmaceutical products (often modified versions of the companies’ own originator biopharmaceuticals) to identify and document which investment and development strategies are being adopted by the top pharmaceutical companies, and to inform their analysis of what they call a “diverse industrial landscape.”
The researchers identified the following 6 investment and development strategies in the global biopharmaceutical market:
Their analysis shows that nearly all of the top 25 biopharmaceutical companies invest in originator biopharmaceuticals and in biotechnology in general, but only half develop next-generation biopharmaceuticals, and only half invest in the development of biosimilars:
The researchers found that the companies do not focus on a single strategy, but are involved in multiple investment and development approaches. “A common strategy to market biopharmaceuticals is collaboration between companies,” the authors report. “These collaborations can as well be used to gain access in regions the company has less experience with.”
With patents now expiring for some of the biggest-selling monoclonal antibodies, the researchers say that the snapshot they have created highlights the interest of companies in investing in the development of these molecules and/or entering into collaborations to create access to these molecules. This study is the first to provide a systematic overview of investment and development strategies adopted by industrial players in the global biopharmaceutical market, according to the authors.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.